MAYWOOD, IL – Hepatitis C drugs improve more than 90 per cent of patients, but can cost more than $ 50,000 per patient.
Perceptions of a new study could lead to significant cost savings. Preliminary data from the study, led by the theoretical modeling researcher from Loyola University Chicago Stritch, School of Medicine and Loyola Medicine, found that the 50% of patients could reduce the standard treatment procedure of 12 weeks before less than six weeks without compromising effectiveness.
"There is potential to save up to 20 per cent of hepatitis C drug costs," said Loyola researcher, Harel Dahari, PhD, co-author of the study together with Ohad Etzion, MD, from the Soroka University Medical Center in Israel. Amir Shlomai, MD, PhD, is a senior author of Beilinson Hospital in Israel.
The study was introduced November 12 during the American Association for the Study of Junior Diseases in San Francisco's annual meeting.
Dr Dahari is joint director of the Program for Experimental and Experimental Modeling (PETM) in the Loyola Medicine hepatology department and Chicago University School of Medicine Loyola University. Two other Loyola authors are Susan Uprichard, PhD, co-director of PETM and associate professor in the microbiology and immunology department and Scott Cotler, MD, head of heyatology department Loyola Medicine and a professor at the medicine department of Loyola, Chicago School of Medicine, Stritch.
Hepatitis C is an infection caused by a virus that is spread through blood that has contaminated. It can lead to liver damage, liver failure and liver cancer. Around 70 million people worldwide, including about three million in the United States, are infected with hepatitis C.
A class of oral medicines known as direct acting anti-viral (DAA) has revolutionized the treatment of hepatitis C. In more than 90 per cent of patients, medicines are eliminating the virus and improving & The patient, with a few side effects. But the high cost limits have access and there is a significant financial burden on Medicare, Medicaid and private insurers.
"The current treatment of moderation is usually for a fixed period of time, 12 weeks, rather than being tailored to the individual patient," said Dr. Cotler.
In the new study, researchers used a personal medicine technique of the name called therapy led on a modeling response to reduce treatment times when that was possible. After patients had been treated for a few weeks, researchers measured the levels of hepatitis C virus levels that had decreased. They use mathematical modeling to estimate how much time it would take to completely eliminate the virus.
The study has included 22 patients to date. Mathematical modeling predicted that the treatment could be reduced to 10 weeks in one patient (five per cent of the total number of patients), eight weeks in eight patients (36 per cent) and six weeks in two patients (nine per cent). The other 11 patients (50 per cent) needed to be treated for the standard 12 weeks.
Twenty-one patients remained free of viruses. The only redundant patient was the most difficult form of the hepatitis C virus, known as genotype 3.
The test-of-concept pilot study showed that using guided therapy responds to reduce treatment times in practice. To verify the results, a large multi-enterprise trial is underway in Israel.
Dr. Dahari, as well as cutting costs, that shorter treatment regimes would make it easier to treat hepatitis C patients with limited health insurance benefits.
The study was carried out with David Yardeni, MD, Anat Nevo-Shor, MD, Daniela Munteanu, MD, and Naim Abufreha, MD, of the Gastroenterology and Disease Department, Soroka University Medical Center, Beesheba, Israel; Assaf Issachar, MD, Michal Cohen-Naftaly, MD, Orly Sneh Arbib, MD, and Marius Braun, MD, the Junior Institute, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel; and Orna Mor, PhD, of the Central Virology Laboratory, the Ministry of Health, Sheba Medical Center, Israel.
The title of the study is "Therapy led by a response with DAA intensifying Treatment in 50 per cent of Patients with HCV Treatment."
The study was partially supported by Clalit, the health service organizer in Israel and the National Health Institutions U.S ..
Disclaimer: AAAS and EurekAlert! they are not responsible for the accuracy of news releases posted to EurekAlert! by contributing organizations or for using any information through the EurekAlert system.